.webp)
Semaglutide activates GLP-1 receptors involved in appetite, satiety, digestion, and metabolic regulation. As treatment progresses, it can help make hunger more predictable, increase satisfaction after meals, and make it easier to stay consistent with appropriate portions. Glycine is included as part of the compounded formulation, while semaglutide remains the active driver of appetite and weight-management support.
Patients may notice:
• More consistent appetite control
• Feeling full sooner during meals
• Less desire to snack between meals
• Fewer cravings
• Less food noise
• Greater consistency with nutrition goals
• Continued weight-management progress
For many patients, this stage begins to feel less like constantly “trying to diet” and more like having better control over hunger.
Before starting Semaglutide + Glycine, your medical prescriber will review your health history, current medications, previous weight-management treatments, and goals to determine the most appropriate treatment plan. Be sure to discuss any history of pancreatitis, gallbladder disease, significant digestive problems, kidney concerns, diabetes-related eye disease, or thyroid cancer, including a personal or family history of medullary thyroid carcinoma or MEN2. Let your provider know if you are pregnant, breastfeeding, planning pregnancy, or taking other medications that affect blood sugar or appetite. Your dose may be adjusted gradually based on tolerance, response, and progress. Prescription required.